ReviewMedical oncology (Northwood, London, England)2010
Mechanism of action of immunomodulatory agents in multiple myeloma.
Review in Medical oncology (Northwood, London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms.Journal of molecular and cellular cardiology · 2024Review
- New immunomodulatory anticancer quinazolinone-based thalidomide analogs: design, synthesis and biological evaluation.Future medicinal chemistry · 2024Article
- Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs.International journal of molecular sciences · 2023Article
- Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview.Metabolites · 2023Review
- Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents.RSC advances · 2022Article
- Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.Clinical case reports · 2022Article
- Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.Cancers · 2021Review
- Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.Drugs · 2017Review
- VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.OncoTargets and therapy · 2017Article
- [Clinical analysis of thalidomide in 36 untreated patients with T-cell lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?OncoTargets and therapy · 2016Review
- Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.Drugs & aging · 2015Review
- Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.Drugs · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Immunomodulatory agents (IMiD's) have become an important drug category in the treatment of multiple myeloma. The agents have a complex mechanism of action that influence the microenvironment in the bone marrow. The microenvironment is an essential promotor of disease progression and therefore important in targeting the disease. The article reviews mechanism of action and essential pathways of IMiD's that are important in disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.